Back

The effect of SGLT2 inhibitor on clinical outcomes in patients with type 2 diabetes and atrial fibrillation

26 August 2023 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Prevention of heart failure Prevention ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Sung-Hee Shin

Inha University Hospital, Incheon (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Association of cardiovascular health with incident heart failure in community population without cardiovascular disease: results of the China PEACE million persons project
Doctor A. Cai (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Estimating the extent to which chronic kidney disease mediates the association between metabolic syndrome and heart failure: the Atherosclerosis Risk in Communities (ARIC) Study
Doctor C. Ndumele (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Hypertension and poor control of systolic blood pressure after a myocardial infarction with non-obstructive coronary arteries are associated with incident heart failure
Miss H. Broo (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Open population approach to identify risk factors and detection of cases of heart failure in Mexico
Doctor L. Aguilera Mora (Guadalajara, MX)
Abstract Slides Video
Presentation thumbnail
Improved heart failure screening and prevention in type 2 diabetes mellitus by cardiologist in rural areas
Doctor A. Klabnik (Namestovo, SK)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention of heart failure

The Event

Event poster

ESC Congress 2023

26 August 2023 08:15 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus
thumbnail
Congress Presentation
Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study
thumbnail
Congress Presentation
Sglt2 inhibitors vs. dpp-4 inhibitors and glp-1 receptor agonists on atrial fibrillation incidence in type 2 diabetes: a meta-analysis